ACTA1 and triple-A syndrome: Furthermore, Western blot analysis indicated that GlycoRNA-NP-siMT1 treatment preserved the expression of α-SMA and SM22a while inhibiting the expression of MMP2, MMP9, OPN, and vimentin in the mouse AAA model (Figs. S8C–I).